0000950170-24-011253.txt : 20240205
0000950170-24-011253.hdr.sgml : 20240205
20240205162135
ACCESSION NUMBER: 0000950170-24-011253
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weber Barbara
CENTRAL INDEX KEY: 0001800670
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39485
FILM NUMBER: 24596004
MAIL ADDRESS:
STREET 1: C/O REVOLUTION MEDICINES, INC.
STREET 2: 700 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tango Therapeutics, Inc.
CENTRAL INDEX KEY: 0001819133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 901
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (857) 320-4900
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 901
CITY: BOSTON
STATE: MA
ZIP: 02215
FORMER COMPANY:
FORMER CONFORMED NAME: BCTG Acquisition Corp.
DATE OF NAME CHANGE: 20200723
4
1
ownership.xml
4
X0508
4
2024-02-01
0001819133
Tango Therapeutics, Inc.
TNGX
0001800670
Weber Barbara
C/O TANGO THERAPEUTICS, INC.,
201 BROOKLINE AVE., SUITE 901
BOSTON
MA
02215
true
true
false
false
Chief Executive Officer
false
Common Stock
2024-02-01
4
A
false
87168
0.00
A
87168
D
Stock Option (Right to Buy)
12.28
2024-02-01
4
A
false
523012
0.00
A
2034-02-01
Common Stock
523012
523012
D
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 3, 2025, 1/3 on February 2, 2026 and 1/3 on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter.
/s/ Douglas Barry, attorney-in-fact
2024-02-05